Check out these hot trials to look out for in 2025!
🔥Moderna – Combination Influenza and COVID-19 Vaccine
An mRNA-based vaccine targeting both influenza and COVID-19 to streamline annual vaccinations. Aims to improve vaccine coverage and adaptability using mRNA technology.
Status: Phase 3 trial results expected in 2025
🔥Beam Therapeutics – Sickle Cell Disease
A second-generation gene-editing therapy using base-editing technology to improve safety and efficacy for sickle cell patients. Aims to build on the success of CRISPR-based therapies with enhanced precision.
Status: Phase 2/3 trials with data expected in 2025
🔥 Pfizer – Duchenne Muscular Dystrophy Gene Therapy
A gene therapy designed to treat Duchenne muscular dystrophy, providing a potential alternative to Sarepta’s FDA-approved therapy. This trial could position Pfizer as a leader in the muscular dystrophy gene therapy space.
Status: Phase 3 trials targeting a more comprehensive dataset
🔥 Vertex Pharmaceuticals – Acute Pain (VX-548)
A small molecule therapy aimed at addressing acute pain without the risks of addiction associated with opioids. If successful, VX-548 could fill a critical gap in non-addictive pain management solutions.
Status: Phase 3 trials expected to yield results in 2025
🔥 Johnson & Johnson – Treatment for Major Depressive Disorder
Development of drugs targeting kappa opioid receptors (KOR) to treat resistant forms of depression. This could introduce a new drug class for depression, filling gaps left by current therapies.
Status: Ongoing Phase 2/3 trials with data anticipated by 2025
🔥 Sanofi – Multiple Sclerosis Treatment (Tolebrutinib)
A BTK inhibitor designed to cross the blood-brain barrier, providing an innovative treatment for multiple sclerosis. This could revolutionize MS treatment, especially for progressive forms of the disease.
Status: Phase 3 trials with results expected in 2025
🔥 Regeneron – Obesity and Metabolic Disorders
A monoclonal antibody therapy aimed at treating obesity and related metabolic syndromes by targeting GDF15 pathways. Part of the growing focus on biologics to address obesity, following the success of GLP-1 receptor agonists like Ozempic.
Status: Advanced trials expected to yield key insights in 2025
🔥 Eli Lilly – Cardiovascular Disease (Tirzepatide)
Assessing the cardiovascular benefits of tirzepatide, a GLP-1 and GIP receptor agonist already approved for diabetes and weight management. Could confirm additional uses for tirzepatide in reducing heart disease risks, expanding its therapeutic reach.
Status: Phase 3 cardiovascular outcome trials progressing toward completion in 2025